# A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

> **NCT05745727** · PHASE1 · COMPLETED · sponsor: **Protalix** · enrollment: 64 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** PRX-115
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05745727
- **Lead sponsor:** Protalix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-23
- **Primary completion:** 2024-08-26
- **Final completion:** 2025-02-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745727, "A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05745727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*